Nagla Abdel Karim, MD (IMAGE)

SWOG Cancer Research Network

Nagla Abdel Karim, MD

Caption

Dr. Nagla Abdel Karim, of the Inova Schar Cancer Institute, led the SWOG S1929 phase 2 trial, which found that among patients with extensive stage small-cell lung cancer that was positive for SLFN11 expression, those who received atezolizumab plus talazoparib had significantly longer progression-free survival times than those who received atezolizumab alone.

Credit

Inova

Usage Restrictions

Credit Inova

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.